KRAS基因突变在胰腺导管腺癌（PDAC）中的高频出现，使其成为研究人员梦寐以求的靶点。然而，这一领域长期以来被视为“不可成药”（undruggable）的难题。随着新技术和新思路的涌现，靶向KRAS的治疗正逐渐成为攻克PDAC的重要突破口。

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist ...

Read on to learn about new genomic biomarkers that could improve prognosis and treatment strategies for pancreatic ductal ...

数据证实，格索雷塞在KRAS G12C突变的NSCLC患者中持续展现出令人振奋的抗肿瘤活性与良好可控的耐受性，为更多患者点亮了精准治疗、深度缓解与长期生存的曙光，成为抗击肿瘤的有力武器及追求更优生活质量的高潜力选项。

Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025 ...

Shares of Verastem Oncology (VSTM) are up over 40% at $5.17 in premarket trading Tuesday, following a regulatory update. The ...

Verastem's promising therapy for LGSOC could position them as a commercial-stage company by 2025. Click here to find out why ...